B+
Bull case
0%
Probability
Target price
$34.00
+48.1% vs current
DFTX
Definium TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-11
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
1%
Probability
Target price
$21.00
-8.5% vs current
B-
Bear case
0%
Probability
Target price
$14.00
-39.0% vs current
AI sentiment snapshot
Latest data as of 2026-04-20
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+39.5
Score
AI commentary
This remains a cautious monitoring-style biotech memo rather than a high-conviction bullish call. The evidence packet is strong on primary-source context, and the 10-K provides tangible support for a real 2026 catalyst calendar: a fully enrolled Phase 3 MDD readout expected in late Q2 2026, second-study activation, a secondary DT402 data hook, and runway management says extends into 2028 [#10-K-2026-02-26]. That said, the deterministic prior is negative, coverage is low, and the near-term setup still depends disproportionately on a small number of clinical proof points. Net sentiment is therefore neutral-to-cautious: the stock has credible upside if the company executes, but current evidence is better suited to a watchlist with defined milestone checkpoints than to an aggressive pre-data thesis.
RankAlpha Sentiment Codex - 2026-04-20
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-04-22eventApril 22, 2026 investor and analyst day may sharpen readout expectationsMedium impact
Definium said its April 22, 2026 investor and analyst day will cover DT120 ODT, anticipated 2026 topline data readouts, and the potential market opportunity. This is less important than actual data, but it can still tighten investor framing around timing, study design, and commercial ambition ahead of the pivotal MDD readout [#PR-2026-03-26].
2026-05-15catalystSecond Phase 3 MDD study activation and expected early Q2 first-patient dosing support durability of the DT120 packageHigh impact
Beyond Emerge, the 10-K says initial sites were activated for Ascend, the second Phase 3 DT120 ODT MDD trial, in Q1 2026 and that first patient dosing is expected by early Q2 2026. Confirmation that Ascend is moving on schedule would improve confidence that any positive Emerge result can be supported by a broader registrational package rather than a one-study narrative [#10-K-2026-02-26].
2026-06-30eventPhase 3 DT120 ODT MDD Emerge topline readout expected in late Q2 2026High impact
The clearest value-driving catalyst is the late-second-quarter 2026 Part A topline readout from Emerge, the company’s first Phase 3 MDD study. The 2026 10-K says Emerge is fully enrolled with 149 participants and that topline results are anticipated in late Q2 2026, making this the main near-term binary for sentiment and valuation [#10-K-2026-02-26].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-20 • Updated nightlySource: Internal modelMethodology